Login to get immediate access to this content.
LoginSpeaker: Giovanni Randon, Italy
Abstract discussed:
- LBA4 - Switch maintenance with ramucirumab plus paclitaxel versus continuation of oxaliplatin-based chemotherapy in advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: Final results and key biomarkers of the ARMANI phase 3 trial - Watch the session from ESMO Gastrointestinal Cancers Congress 2024 now
The speakers and studies featured in this video series were selected independently by ESMO.
Published July 2024